Evidence map›Paper›PMID 26683888›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2016

Associations of Urinary Uromodulin with Clinical Characteristics and Markers of Tubular Function in the General Population.

Menno Pruijm, Belen Ponte, Daniel Ackermann, Fred Paccaud, Idris Guessous, Georg Ehret, Antoinette Pechère-Bertschi, Bruno Vogt, Markus G Mohaupt, Pierre-Yves Martin and 7 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06876298 (Role of Uromodulin in Management of Multiple Myloma), which is not on this map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06876298 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Role of Uromodulin in Management of Multiple Myloma

TypeinterventionalSponsorAssiut UniversityRan2025 to 2027Enrolled30ConditionsMultiple MylomaArms- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 120 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Endocrine regulation of uromodulin in aging.Frontiers in endocrinology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Uromodulin modulates mitochondria and kidney tubule resilience.The Journal of clinical investigation · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Kidney international reports · 2024
    Article
  18. Uromodulin and the study of urinary extracellular vesicles.Journal of extracellular biology · 2024
    Review
  19. Article
  20. Hypertension (Dallas, Tex. : 1979) · 2024
    Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Menno PruijmDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Belen PonteDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Daniel AckermannDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Fred PaccaudDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Idris GuessousDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Georg EhretDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Antoinette Pechère-BertschiDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Bruno VogtDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Markus G MohauptDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Pierre-Yves MartinDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Sonia C YouhannaDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Nadine NägeleDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Peter VollenweiderDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Gérard WaeberDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Michel BurnierDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Olivier DevuystDue to the number of contributing authors, the affiliations are provided in the Supplemental Material. murielle.bochud@chuv.ch olivier.devuyst@uzh.ch.
Murielle BochudDue to the number of contributing authors, the affiliations are provided in the Supplemental Material. murielle.bochud@chuv.ch olivier.devuyst@uzh.ch.
Institute of Social and Preventive Medicine · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAllelic variants in UMOD, the gene coding for uromodulin, are associated with rare tubulointerstitial kidney disorders and risk of CKD and hypertension in the general population. The factors associated with uromodulin excretion in the normal population remain largely unknown, and were therefore explored in this study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Urinary uromodulin excretion was measured using a validated ELISA in two population-based cohorts that included more than 6500 individuals. The Swiss Kidney Project on Genes in Hypertension study (SKIPOGH) included 817 adults (mean age±SD, 45±17 years) who underwent renal ultrasonography and performed a 24-hour urine collection. The Cohorte Lausannoise study included 5706 adults (mean age, 53±11 years) with fresh spot morning urine samples. We calculated eGFRs using the CKD-Epidemiology Collaboration formula and by 24-hour creatinine clearance.

resultsIn both studies, positive associations were found between uromodulin and urinary sodium, chloride, and potassium excretion and osmolality. In SKIPOGH, 24-hour uromodulin excretion (median, 41 [interquartile range, 29-57] mg/24 h) was positively associated with kidney length and volume and with creatinine excretion and urine volume. It was negatively associated with age and diabetes. Both spot uromodulin concentration and 24-hour uromodulin excretion were linearly and positively associated (multivariate analyses) with eGFR<90 ml/min per 1.73 m(2).

conclusionAge, creatinine excretion, diabetes, and urinary volume are independent clinical correlates of urinary uromodulin excretion. The associations of uromodulin excretion with markers of tubular functions and kidney dimensions suggest that it may reflect tubule activity in the general population.

Indexed as

AdultAgedAlbuminuriaBiomarkersElectrolytesFemaleGlomerular Filtration RateHumansKidney TubulesMaleMiddle AgedOsmolar ConcentrationUromodulinBiomarkersElectrolytesUromodulinelectrolytesglomerular filtration ratehumanshypertension, renalosmolalitypotassiumrenal insufficiency, chronicrenal tubular cellssodiumuromodulin

Identifiers

PMID26683888
PMCPMC4702229
OpenAlexW2225514345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.